Pseudomonas aeruginosa and lung function decline in patients with bronchiectasis

Area of Science:

• Pulmonology
• Respiratory Medicine
• Clinical Epidemiology

Background:

• Bronchiectasis is a chronic respiratory condition characterized by irreversible airway dilation.
• Lung function decline is a significant marker of disease progression and prognosis in bronchiectasis.
• Identifying factors influencing lung function decline is crucial for effective management.

Purpose of the Study:

• To analyze the rate of lung function decline over time in a cohort of bronchiectasis patients.
• To identify clinical factors associated with accelerated forced expiratory volume in the first second (FEV1) decline.
• To provide insights into prognostic indicators for bronchiectasis progression.

Main Methods:

• An observational, prospective study involving 849 patients from the Spanish Bronchiectasis Registry (RIBRON).
• Annual spirometry measurements were conducted, with forced expiratory volume in the first second (FEV1) as the primary outcome.
• Mixed-effects linear regression models were used to analyze FEV1 decline, adjusting for relevant clinical variables.

Main Results:

• The mean annual rate of FEV1 decline was -31.6 mL/year.
• Faster FEV1 decline was observed in patients with chronic Pseudomonas aeruginosa infection (-52.1 mL/year) compared to uninfected patients (-24.6 mL/year).
• Accelerated decline was also associated with older age, a higher number of severe exacerbations in the prior year, and a higher baseline FEV1.

Conclusions:

• The annual decline in lung function for bronchiectasis patients is approximately -31.6 mL/year.
• Chronic Pseudomonas aeruginosa infection, older age, a history of severe exacerbations, and higher baseline FEV1 are significant predictors of faster lung function decline.
• These findings underscore the importance of monitoring and managing these factors to potentially slow disease progression in bronchiectasis.